172@29@17@240!~!172@29@0@53!~!|news|aurobindopharma|business-AP-6months.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
Moneycontrol
business
Jump to
9 Results Found
  • No scope of US intervention in Indian pharma cos: Wockhardt Jan 12, 2017 01:07 PM IST

    No scope of US intervention in Indian pharma cos: Wockhardt

    Wockhardt chief Habil Khorakiwala says that Indian generic company as a whole is a competitive industry in US and therefore there is no scope for government intervention there. Anmol Ganjoo of JM Financial says if drug prices come down then Indian pharma companies will benefit.

  • Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal Dec 20, 2016 10:50 AM IST

    Aurobindo's Hyd unit getting form 483 a non-event: Surajit Pal

    USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.

  • US FDA completes Aurobindo's Unit 4 audit; to help boost US biz Sep 19, 2016 02:56 PM IST

    US FDA completes Aurobindo's Unit 4 audit; to help boost US biz

    Surajit Pal, Pharma Analyst at Prabhudas Lilladher told CNBC-TV18 that this is good news for Aurobindo as this plant has almost 26 percent of pending approvals which are important drivers for its US business.

  • Aurobindo's topline can swell by $350 m with Teva buy: PL Aug 29, 2016 03:07 PM IST

    Aurobindo's topline can swell by $350 m with Teva buy: PL

    Indian pharmaceutical companies Aurobindo and Intas are among the final contenders for Teva‘s generic drug business in UK. The strategy will help the companies expand their European business.

  • Lupin to see approvals after US FDA gives clean chit: Macquarie Jul 08, 2016 09:11 AM IST

    Lupin to see approvals after US FDA gives clean chit: Macquarie

    Of the total 18 observations, 9 from July 2015 and another 9 from March 2016 inspection, the former ones relating to equipment and warehousing have been closed. Nine observations are still outstanding for the company.

  • Sun's psoriasis trial drug won't hit mkt before FY19: Analyst May 05, 2016 10:33 AM IST

    Sun's psoriasis trial drug won't hit mkt before FY19: Analyst

    Sun Pharma has completed a 12 weeks trial of its psoriasis drug, MK 3222, but needs 52-124 weeks data to apply for a license with the US FDA, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

  • 20% of Cipla FY17 revenues to come from US: Chirag Talati Feb 23, 2016 01:47 PM IST

    20% of Cipla FY17 revenues to come from US: Chirag Talati

    When asked about the Cipla Indore facility, which has come under the USFDA scanner for manufacturing norms violations, Talati reassures that the facility is not a major contributer to Cipla earnings. Hence this news, he feels should not affect sales.

  • Pharma cos facing pricing pressure in US: PhillipCap Nov 09, 2015 12:36 PM IST

    Pharma cos facing pricing pressure in US: PhillipCap

    In an interview with CNBC-TV18, Surya Patra, Vice President Pharma - Institutional Equity Research at Phillipcapital, says that the company has cut its FY17 estimates for Sun Pharma by 5 percent.

  • Sun's margins may reduce to 30-32% post merger: Surajit Pal Dec 29, 2014 12:36 PM IST

    Sun's margins may reduce to 30-32% post merger: Surajit Pal

    As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.

Sections